Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Financing Activities (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Cash from Financing Activities for 6 consecutive years, with -$41685.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 119.21% year-over-year to -$41685.0, compared with a TTM value of $168.3 million through Dec 2025, up 14452.36%, and an annual FY2025 reading of $168.3 million, up 14452.36% over the prior year.
  • Cash from Financing Activities was -$41685.0 for Q4 2025 at SAB Biotherapeutics, down from $168.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $168.7 million in Q3 2025 and bottomed at -$6.3 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $13.5 million, with a median of -$157076.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 37883.67% in 2021, then plummeted 13794.46% in 2022.
  • Year by year, Cash from Financing Activities stood at $36.0 million in 2021, then plummeted by 76.72% to $8.4 million in 2022, then soared by 706.4% to $67.6 million in 2023, then tumbled by 99.68% to $216961.0 in 2024, then tumbled by 119.21% to -$41685.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for SABS at -$41685.0 in Q4 2025, $168.7 million in Q3 2025, and -$173844.0 in Q2 2025.